scholarly journals SQ3370 Activates Cytotoxic Drug via Click Chemistry at Tumor and Elicits Sustained Responses in Injected & Non-injected Lesions

2020 ◽  
Author(s):  
S. Srinivasan ◽  
N. A. Yee ◽  
K. Wu ◽  
M. Zakharian ◽  
A. Mahmoodi ◽  
...  
Keyword(s):  
Click Chemistry ◽  
Tumor Response ◽  
Maximum Dose ◽  
Tumor Characteristics ◽  
Antitumor Response ◽  
Metastatic Lesions ◽  
Specific Tumor ◽  
Lead Candidate ◽  
Sustained Responses ◽  
Single Lesion

AbstractWhile systemic immuno-oncology therapies have shown remarkable success, only a limited subset of patients benefit from them. Our Click Activated Protodrugs Against Cancer (CAPAC™) Platform is a click chemistry-based approach that activates cancer drugs at a specific tumor with minimal systemic toxicity. CAPAC Platform is agnostic to tumor characteristics that can vary across patients and hence applicable to several types of tumors. We describe the benefits of SQ3370 (lead candidate of CAPAC) to achieve systemic anti-tumor responses in mice bearing two tumors. SQ3370 consists of a biopolymer, injected in a single lesion, followed by systemic doses of an attenuated protodrug of doxorubicin (Dox). SQ3370 was well-tolerated at 5.9-times the maximum dose of conventional Dox, increased survival by 63% and induced a systemic antitumor response against injected and non-injected lesions. The sustained anti-tumor response also correlated with immune activation measured at both lesions. SQ3370 could potentially benefit patients with micro-metastatic lesions.

scholarly journals SQ3370 Activates Cytotoxic Drug via Click Chemistry at Tumor and Elicits Sustained Responses in Injected and Non‐Injected Lesions

2021 ◽  
pp. 2000243
Author(s):  
Sangeetha Srinivasan ◽  
Nathan Alexander Yee ◽  
Kui Wu ◽  
Michael Zakharian ◽  
Amir Mahmoodi ◽  
...  
Keyword(s):  
Click Chemistry ◽  
Cytotoxic Drug ◽  
Sustained Responses

scholarly journals Response to neoadjuvant treatment among rectal cancer patients in a population-based cohort

2020 ◽  
Vol 36 (1) ◽  
pp. 177-185
Author(s):  
Elizabeth Alwers ◽  
Lina Jansen ◽  
Jakob Kather ◽  
Efrat Amitay ◽  
Hendrik Bläker ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Cancer Patients ◽  
Tumor Response ◽  
Patient Survival ◽  
Neoadjuvant Treatment ◽  
Population Based ◽  
Pathological Examination ◽  
Study Patient ◽  
Molecular Characteristics ◽  
Tumor Characteristics

Abstract Background In rectal cancer, prediction of tumor response and pathological complete response (pCR) to neoadjuvant treatment could contribute to refine selection of patients who might benefit from a delayed- or no-surgery approach. The aim of this study was to explore the association of clinical and molecular characteristics of rectal cancer with response to neoadjuvant treatment and to compare patient survival according to level of response. Methods Resected rectal cancer patients were selected from a population-based cohort study. Molecular tumor markers were determined from the surgical specimen. Tumor response and pCR were defined as downstaging in T or N stage and absence of tumor cells upon pathological examination, respectively. The associations of patient and tumor characteristics with tumor response and pCR were explored, and patient survival was determined by degree of response to neoadjuvant treatment. Results Among 1536 patients with rectal cancer, 602 (39%) received neoadjuvant treatment. Fifty-five (9%) patients presented pCR, and 239 (49%) and 250 (53%) patients showed downstaging of the T and N stages, respectively. No statistically significant associations were observed between patient or tumor characteristics and tumor response or pCR. Patients who presented any type of response to neoadjuvant treatment had significantly better cancer-specific and overall survival compared with non-responders. Conclusion In this study, patient characteristics were not associated with response to neoadjuvant treatment, and molecular characteristics determined after surgical resection of the tumor were not predictive of pCR or tumor downstaging. Future studies should include molecular biomarkers from biopsy samples before neoadjuvant treatment.

scholarly journals Assessment of Pathological Response of Breast Carcinoma in Modified Radical Mastectomy Specimens after Neoadjuvant Chemotherapy

2015 ◽  
Vol 2015 ◽  
pp. 1-8 ◽  
Author(s):  
Dhanya Vasudevan ◽  
P. S. Jayalakshmy ◽  
Suresh Kumar ◽  
Siji Mathew
Keyword(s):  
Breast Carcinoma ◽  
Neoadjuvant Chemotherapy ◽  
Lymph Nodes ◽  
Tumor Response ◽  
Ductal Carcinoma ◽  
Locally Advanced ◽  
Radical Mastectomy ◽  
Tumor Characteristics ◽  
Modified Radical Mastectomy ◽  
Tumor Bed

Aim. Paclitaxel based neoadjuvant chemotherapy regimen (NAT) in the setting of locally advanced breast cancer (LABC) can render inoperable tumor (T4, N2/N3) resectable. The aim of this study was to assess the status of carcinoma in the breast and lymph nodes after paclitaxel based NAT in order to find out the patient and the tumor characteristics that correspond to the pathological responses which could be used as a surrogate biomarker to assess the treatment response.Materials and Methods. Clinical and tumor characteristics of patients with breast carcinoma (n=48) were assessed preoperatively. These patients were subjected to modified radical mastectomy after 3 courses of paclitaxel based NAT regimen. The pathological responses of the tumor in the breast and the lymph nodes were studied by using Chevallier’s system which graded the responses into pathological complete response (pCR), pathological partial response (pPR), and pathological no response (pNR).Results. Our studies showed a pCR of 27.1% and a pPR of 70.9% . Clinically small sized tumors (2–5 cms) and Bloom Richardson’s grade 1 tumors showed a pCR. Mean age at presentation was 50.58 yrs. 79.2% of cases were invasive ductal carcinoma NOS; only 2.1% were invasive lobular carcinoma, their response to NAT being the same. There was no downgrading of the tumor grades after NAT. Ductal carcinoma in situ and lymphovascular invasion were found to be resistant to chemotherapy. The histopathological changes noted in the lymph nodes were similar to that found in the tumor bed.Discussion and Conclusion. From our study we conclude that histopathological examination of the tumor bed is the gold standard for assessing the chemotherapeutic tumor response. As previous studies have shown pCR can be used as a surrogate biomarker to assess the tumor response.

scholarly journals Predicting Tumor Response to Radiotherapy Based on Estimation of Non-Treatment Parameters

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Yutian Huang ◽  
Allison Lewis
Keyword(s):  
Treatment Efficacy ◽  
Tumor Response ◽  
Synthetic Data ◽  
Response To Treatment ◽  
Tumor Characteristics ◽  
Patient Response ◽  
Differential Equation Models ◽  
Tumor Remission ◽  
Parameter Distributions ◽  
Complete Tumor

Though clinicians can now collect detailed information about a variety of tumor characteristics as a tumor evolves, it remains difficult to predict the efficacy of a given treatment prior to administration. Additionally, the process of data collection may be invasive and expensive. Thus, the creation of a framework for predicting patient response to treatment using only information collected prior to the start of treatment could be invaluable. In this study, we employ ordinary differential equation models for tumor growth and utilize synthetic data from a cellular automaton model for calibration. We investigate which parameters have the most influence upon treatment efficacy by comparing parameter distributions associated with treatment outcomes. Additionally, we develop a framework for estimating the probability of observing complete tumor remission following a simulated radiotherapy regimen based only on a patient’s non-treatment parameters, so that treatment efficacy could be predicted prior to administration.

Review and Prospect of Tissue-agnostic targeted Strategies in Anticancer therapies

2020 ◽  
Vol 20 ◽  
Author(s):  
Peng Yu ◽  
Tao Hongxun ◽  
Gao Yuanqing ◽  
Yang Yuanyuan ◽  
Chen Zhiyong
Keyword(s):  
Targeted Therapy ◽  
Drug Targets ◽  
Anatomical Location ◽  
Tumor Characteristics ◽  
Genetic Characteristics ◽  
Drug Candidates ◽  
Specific Tumor ◽  
Approved Drugs ◽  
Fda Approved Drugs ◽  
Prevalence Of Cancer

: Due to the increasing prevalence of cancer year by year, and the complexity and refractory nature of the disease itself, it is required to constantly innovate the development of new cancer treatment schemes. At the same time, the understanding of cancers has deepened, from the use of chemotherapy regimens with high toxicity and side effects, to the popularity of targeted drugs with specific targets, to precise treatments based on tumor characteristics rather than traditional anatomical location classification. In precision medical, in the view of the specific tumor diseases and their biological characteristics, it has great potential to develop tissue-agnostic targeted therapy with broad-spectrum anticancer significance. The present review has discussed tissue-agnostic targeted therapy based on the biological and genetic characteristics of cancers, expounded its theoretical basis and strategies for drug development. And the feasible drug targets, FDA-approved drugs, as well as drug candidates in clinical trials have also been summarized. In conclusion, the “tissue-agnostic targeted therapy” is a breakthrough in anticancer therapies.

Single-Lesion Measurement per Organ for Assessing Tumor Response in Advanced Gastric Cancer

Oncology ◽  
2014 ◽  
Vol 88 (2) ◽  
pp. 69-75 ◽  
Author(s):  
Hyeong Su Kim ◽  
Ji Won Kim ◽  
Jung Han Kim ◽  
Dae Ro Choi ◽  
A. Rum Han ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Tumor Response ◽  
Single Lesion

scholarly journals Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma

Liver Cancer ◽  
2019 ◽  
Vol 8 (6) ◽  
pp. 480-490 ◽  
Author(s):  
Li-Chun Lu ◽  
Chiun Hsu ◽  
Yu-Yun Shao ◽  
Yee Chao ◽  
Chia-Jui Yen ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitors ◽  
Tumor Response ◽  
Checkpoint Inhibitors ◽  
Specific Tumor ◽  
Organ Specific

scholarly journals Remote multiple intracranial hemorrhage in multiple metastatic lung adenocarcinoma following decompression of posterior fossa lesion: Unknown cause

2015 ◽  
Vol 06 (04) ◽  
pp. 583-585
Author(s):  
Subhas Konar ◽  
R. Arun Babu ◽  
Dhaval P. Shukla ◽  
B Indira Devi
Keyword(s):  
Lung Cancer ◽  
Lung Adenocarcinoma ◽  
Surgical Resection ◽  
Posterior Fossa ◽  
Intracranial Hemorrhage ◽  
Surgical Decompression ◽  
Cerebral Metastasis ◽  
Metastatic Lesions ◽  
Metastatic Lung ◽  
Single Lesion

ABSTRACTCerebral metastasis can present with hemorrhage. However, multiple hemorrhages in metastatic lesions following surgical decompression of a single lesion are never reported. We report a case of cerebral metastasis from lung cancer that developed multiple hemorrhages in supratentorial metastatic lesions following surgical resection of an infratentorial lesion.

scholarly journals Brain Metastases from Gynecological Cancers: Factors that Affect Overall Survival

2002 ◽  
Vol 1 (4) ◽  
pp. 305-310 ◽  
Author(s):  
Ashraf S. Mahmoud-Ahmed ◽  
Patrick A. Kupelian ◽  
Chandana A. Reddy ◽  
John H. Suh
Keyword(s):  
Overall Survival ◽  
Brain Metastases ◽  
Focal Therapy ◽  
Tumor Characteristics ◽  
Gynecological Cancers ◽  
Whole Brain Radiation ◽  
Improved Outcomes ◽  
Brain Radiation ◽  
The Brain ◽  
Single Lesion

We retrospectively reviewed factors that affected overall survival for patients with gynecological cancers that had metastasized to the brain. Between January 1985 to November 1999, we treated 25 patients with brain metastases from gynecological malignancies (cervix n=6, endometrium n=10, and ovary n=9). Various patient and tumor characteristics were identified and analyzed for their significance. Median age was 46 years old (range, 37–78 years) with the majority of tumors being adenocarcinoma (20/25 patients). The treatment consisted of whole brain radiation therapy (WBRT) in 11 patients, focal therapy (surgery and/or stereotactic radiosurgery [SRS]) in 6 patients, and combination therapy (WBRT and surgery and/or SRS) in 8 patients and resulted in median survivals of 6 months, 7 months and 11 months, respectively. Overall median survival was 7.3 months (range, 1 to 88 months). Cause of death was systemic in 9, neurologic in 8 and progression of primary in 2. Those with single lesions had better median survivals compared to those with multiple lesions (17 months vs. 3 months, p=0.017). Our results suggest that patients with a single lesion had improved outcomes. We encourage enrollment of patients with brain metastases onto prospective clinical trials.

Sign in / Sign up

Export Citation Format

Share Document